

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Parathyroid Hormone, Phosphorous, Calcium and Magnesium Testing

Policy Number: CPCPLAB055

Version 1.0

Approval Date: April 29, 2024

Plan Effective Date: January 15, 2025

Description

BCBSNM has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. Serum intact parathyroid/PTH testing **may be reimbursable** in **any** of the following situations:
 - a. To assess for possible hyperparathyroidism in individuals with hypercalcemia;
 - b. To assess post-operative results of parathyroid surgery;
 - c. As part of annual testing of an individual previously diagnosed with hyperparathyroidism;
 - d. As part of an assessment of chronic kidney disease/CKD;
 - e. As part of an assessment of osteoporosis;
 - f. As part of a diagnosis and/or an assessment of cancer or cancer therapy.
2. For individuals suspected of having hypoparathyroidism, pseudohypoparathyroidism, or a related disorder, serum intact parathyroid/PTH testing (See Note 1), **may be reimbursable** in **any** of the following situations:
 - a. In the initial assessment and diagnosis of the disorders listed in Note 1;
 - b. To monitor disease and/or therapy.
3. Serum intact parathyroid/PTH testing to screen for asymptomatic hyperparathyroidism **is not reimbursable**.
4. For individuals presenting for a wellness or a general scam without abnormal findings, the following tests **are not reimbursable**:
 - a. Serum, blood, or fecal magnesium testing;
 - b. Serum phosphorus or phosphate testing;
 - c. Urine phosphorus or phosphate testing;
 - d. Serum total calcium, serum ionized calcium, or urine calcium testing;
 - e. Serum parathyroid hormone testing.
5. Testing serum for truncated parathyroid hormone metabolites, (e.g., amino-terminal and carboxy-terminal fragments), **is not reimbursable**.

NOTE 1: Conditions of hypoparathyroidism, pseudohypoparathyroidism, and related disorders (Mantovani et al., 2018)

1. Hypoparathyroidism
2. Pseudohypoparathyroidism Type 1A (PHP1A)—due to maternal loss of function mutation at the *GNAS* coding sequence
3. Pseudohypoparathyroidism Type 1B (PHP1B)—due to methylation defect at the *GNAS* coding sequence
4. Pseudopseudohypoparathyroidism (PPHP)—due to paternal loss of function mutation at the *GNAS* coding sequence
5. Progressive Osseous Heteroplasia (POH)—due to paternal loss of function mutation at the *GNAS* coding sequence

6. Acrodysostosis (ACRDYS1)—due to mutation in *PRKAR1A*
7. Acrodysostosis (ACRDYS2)—due to mutation in *PDE4D*

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
82310, 82330, 82340, 83735, 83970, 84100, 84105

References:

- Almond, A., Ellis, A. R., & Walker, S. W. (2012). Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. *Ann Clin Biochem*, 49(Pt 1), 63-67. <https://doi.org/10.1258/acb.2011.011094>
- Bensalah, M., Bouayadi, O., Rahmani, N., Lyagoubi, A., Lamrabet, S., & Choukri, M. (2018). Comparative study of the serum measurement of PTH on Roche Cobas e411((R)) versus the Abbott Architect ci8200((R)). *Ann Biol Clin (Paris)*, 76(1), 61-67. <https://doi.org/10.1684/abc.2017.1309> (Etude comparative du dosage de la PTH serique sur Architect ci8200((R)) versus Cobas e411((R)).)
- Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, J. T., Jr. (2014). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. *J Clin Endocrinol Metab*, 99(10), 3561-3569. <https://doi.org/10.1210/jc.2014-1413>
- Bilezikian, J. P., Khan, A. A., Clarke, B. L., Mannstadt, M., Potts, J. T., & Brandi, M. L. (2022). The Fifth International Workshop on the Evaluation and Management of Primary Hyperparathyroidism. *Journal of Bone and Mineral Research*, 37(11), 2290-2292. <https://doi.org/10.1002/jbmr.4670>
- Bislev, L. S., Langagergaard Rodbro, L., Sikjaer, T., & Rejnmark, L. (2019). Effects of Elevated Parathyroid Hormone Levels on Muscle Health, Postural Stability and Quality of Life in Vitamin D-Insufficient Healthy Women: A Cross-Sectional Study. *Calcif Tissue Int*, 105(6), 642-650. <https://doi.org/10.1007/s00223-019-00612-2>
- Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., Pessah-Pollack, R., McClung, M., Wimalawansa, S. J., & Watts, N. B. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. *Endocrine Practice*, 26, 1-46. <https://doi.org/10.4158/GL-2020-0524SUPPL>
- Curhan, G. C., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2001). Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. *Kidney Int*, 59(6), 2290-2298. <https://doi.org/10.1046/j.1523-1755.2001.00746.x>
- Eisen, A., Somerfield, M. R., Accordino, M. K., Blanchette, P. S., Clemons, M. J., Dhesy-Thind, S., Dillmon, M. S., D'Oronzo, S., Fletcher, G. G., Frank, E. S., Hallmeyer, S.,

- Makhoul, I., Moy, B., Thawer, A., Wu, J. Y., & Poznak, C. H. V. (2022). Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. *Journal of Clinical Oncology*, *40*(7), 787-800. <https://doi.org/10.1200/jco.21.02647>
- Fuleihan, G. E.-H., & Juppner, H. (2024, 1/29/2024). *Parathyroid hormone assays and their clinical use*. Wolters Kluwer. <https://www.uptodate.com/contents/parathyroid-hormone-assays-and-their-clinical-use>
- Fuleihan, G. E.-H., & Silverberg, S. J. (2023, Sep 28, 2023). *Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation*. Wolters Kluwer. <https://www.uptodate.com/contents/primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation>
- Gonzalez-Campoy, J. M., St Jeor, S. T., Castorino, K., Ebrahim, A., Hurley, D., Jovanovic, L., Mechanick, J. I., Petak, S. M., Yu, Y. H., Harris, K. A., Kris-Etherton, P., Kushner, R., Molini-Blandford, M., Nguyen, Q. T., Plodkowski, R., Sarwer, D. B., & Thomas, K. T. (2013). Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. *Endocr Pract*, *19* Suppl 3, 1-82. <https://doi.org/10.4158/ep13155.Gl>
- Hamedanian, L., Badehnoosh, B., Razavi-Khorasani, N., Mohammadpour, Z., & Mozaffari-Khosravi, H. (2019). Evaluation of vitamin D status, parathyroid hormone, and calcium among Iranian pregnant women with preeclampsia: A case-control study. *Int J Reprod Biomed (Yazd)*, *17*(11), 831-840. <https://doi.org/10.18502/ijrm.v17i10.5494>
- Han, C. H., Fry, C. H., Sharma, P., & Han, T. S. (2019). A clinical perspective of parathyroid hormone related hypercalcaemia. *Rev Endocr Metab Disord*. <https://doi.org/10.1007/s11154-019-09529-5>
- Hanon, E. A., Sturgeon, C. M., & Lamb, E. J. (2013). Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. *Clin Chem Lab Med*, *51*(10), 1925-1941. <https://doi.org/10.1515/cclm-2013-0315>
- Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., . . . Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, *145*(18), e895-e1032. <https://doi.org/doi:10.1161/CIR.0000000000001063>
- Hernandez-Becerra, E., Jimenez-Mendoza, D., Mutis-Gonzalez, N., Pineda-Gomez, P., Rojas-Molina, I., & Rodriguez-Garcia, M. E. (2020). Calcium Deficiency in Diet Decreases the Magnesium Content in Bone and Affects Femur Physicochemical Properties in Growing Rats. *Biol Trace Elem Res*. <https://doi.org/10.1007/s12011-019-01989-9>
- Jason R Stubbs, A. S. L. Y., MB, BChir. (2024, 1/26/2024). *Hypophosphatemia: Evaluation and treatment*.

<https://www.uptodate.com/contents/hypophosphatemia-evaluation-and-treatment>

- Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Bell, D. S. H., Mechanick, J. I., Pessah-Pollack, R., Smith, D., Fazio, S., & Davidson, M. (2017). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. *Endocrine Practice*, 23.
<https://pro.ace.com/pdfs/education/lipid-guidelines.pdf>
- KDIGO. (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*, 3(1), v - 150.
https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
- KDIGO. (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). *Kidney Int*, 7(1), 1-59. <https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf>
- Konishi, H., Fujiwara, H., Itoh, H., Shiozaki, A., Arita, T., Kosuga, T., Morimura, R., Komatsu, S., Ichikawa, D., Okamoto, K., & Otsuji, E. (2018). Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma. *Oncol Lett*, 15(1), 658-664.
<https://doi.org/10.3892/ol.2017.7345>
- Kreepala, C., Kitporntheranunt, M., Sangwipasnapaporn, W., Rungsrithananon, W., & Wattanavaekin, K. (2018). Assessment of preeclampsia risk by use of serum ionized magnesium-based equation. *Ren Fail*, 40(1), 99-106.
<https://doi.org/10.1080/0886022x.2017.1422518>
- Leder, B. Z. (2017). Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. *Curr Osteoporos Rep*, 15(2), 110-119.
<https://doi.org/10.1007/s11914-017-0353-4>
- Lederer, E. (2014). Regulation of serum phosphate. *J Physiol*, 592(18), 3985-3995.
<https://doi.org/10.1113/jphysiol.2014.273979>
- Magee, L. A., Pels, A., Helewa, M., Rey, E., & von Dadelszen, P. (2014). Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can*, 36(5), 416-441.
[https://doi.org/10.1016/s1701-2163\(15\)30588-0](https://doi.org/10.1016/s1701-2163(15)30588-0)
- Magee, L. A., Smith, G. N., Bloch, C., Côté, A. M., Jain, V., Nerenberg, K., von Dadelszen, P., Helewa, M., & Rey, E. (2022). Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. *J Obstet Gynaecol Can*, 44(5), 547-571.e541.
<https://doi.org/10.1016/j.jogc.2022.03.002>
- Mancuso, E., Perticone, M., Spiga, R., Averta, C., Rubino, M., Fiorentino, T. V., Miceli, S., Mannino, G. C., Sciacqua, A., Succurro, E., Perticone, F., Sesti, G., & Andreozzi, F. (2020). Association between Serum Mg(2+) Concentrations and Cardiovascular Organ Damage in a Cohort of Adult Subjects. *Nutrients*, 12(5), 1264.
<https://doi.org/10.3390/nu12051264>
- Mannstadt, M. (2023, March 24). *Parathyroid hormone secretion and action*. Wolters Kluwer. Retrieved 01/18/2023 from <https://www.uptodate.com/contents/parathyroid-hormone-secretion-and-action>

- Mantovani, G., Bastepe, M., Monk, D., de Sanctis, L., Thiele, S., Usardi, A., Ahmed, S. F., Bufo, R., Choplin, T., De Filippo, G., Devernois, G., Eggermann, T., Elli, F. M., Freson, K., Garcia Ramirez, A., Germain-Lee, E. L., Groussin, L., Hamdy, N., Hanna, P., . . . Linglart, A. (2018). Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. *Nat Rev Endocrinol*. <https://doi.org/10.1038/s41574-018-0042-0>
- Mantovani, G., Bastepe, M., Monk, D., de Sanctis, L., Thiele, S., Ahmed, S. F., Bufo, R., Choplin, T., De Filippo, G., Devernois, G., Eggermann, T., Elli, F. M., Garcia Ramirez, A., Germain-Lee, E. L., Groussin, L., Hamdy, N. A. T., Hanna, P., Hiort, O., Jüppner, H., . . . Linglart, A. (2020). Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. *Hormone Research in Paediatrics*, *93*(3), 182-196. <https://doi.org/10.1159/000508985>
- Marcucci, G., Della Pepa, G., & Brandi, M. L. (2017). Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. *Expert Opin Drug Saf*, *16*(5), 617-625. <https://doi.org/10.1080/14740338.2017.1311322>
- Mayo. (2018a). *Calcium, 24 Hour, Urine*. Mayo Foundation for Medical Education and Research. Retrieved 07/02/2018 from <https://www.mayocliniclabs.com/test-catalog/overview/610595>
- Mayo. (2018b, 2018). *Magnesium, Serum*. Mayo Foundation for Medical Education and Research. Retrieved 07/02/2018 from <https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8448>
- Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., Urman, R. D., Adams, S., Cleek, J. B., Correa, R., Figaro, M. K., Flanders, K., Grams, J., Hurley, D. L., Kothari, S., . . . Still, C. D. (2019). CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. *Endocr Pract*, *25*(12), 1346-1359. <https://doi.org/10.4158/gl-2019-0406>
- NCCMH. (2023). National Institute for Health and Care Excellence: Clinical Guidelines. In *Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care*. British Psychological Society (c) The British Psychological Society & The Royal College of Psychiatrists, 2014. <https://www.nice.org.uk/guidance/cg185>
- NCCN. (2023a, October 09, 2023). *Acute Lymphoblastic Leukemia Version 3.2023*. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
- NCCN. (2023b, January 26, 2024). *Esophageal and Esphagogastric Junction Cancers - Version 4.2023*. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
- NCCN. (2023c, August 2, 2023). *Neuroendocrine and Adrenal Tumors Version 1.2023*. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

- NCCN. (2023d, September 7, 2023). *Prostate Cancer - Version 4.2023*.
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
- NCCN. (2024a, August 7, 2023). *Bone Cancer - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
- NCCN. (2024b, January 25, 2024). *Breast Cancer - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- NCCN. (2024c, November 3, 2024). *Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
- NCCN. (2024d, January 03, 2024). *Kidney Cancer - Version 2.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
- NCCN. (2024e, November 1, 2023). *Multiple Myeloma Version 2. 2024*.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
- NCCN. (2024f, September 06, 2023). *Occult Primary (Cancer of Unknown Primary [CUP]) - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf
- NCCN. (2024g). *Systemic Light Chain Amyloidosis - Version 2.2024*. Retrieved 12/12/23
 from https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
- NCCN. (2024h, December 21, 2023). *T-Cell Lymphomas - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf
- NCCN. (2024i, February 1, 2024). *Thyroid Carcinoma - Version 1.2024*.
https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
- NICE. (2021, November 24). *Chronic kidney disease: assessment and management*.
 National Institute for Health and Clinical Excellence (UK) Copyright (c) National
 Institute for Health and Clinical Excellence, 2013.
<https://www.nice.org.uk/guidance/ng203>
- NICE. (2022, June 22). *Multiple sclerosis in adults: management*.
<https://www.nice.org.uk/guidance/ng220>
- NICE. (2023). National Institute for Health and Care Excellence: Clinical Guidelines. In
Suspected Cancer: Recognition and Referral. National Institute for Health and Care
 Excellence (UK) Copyright (c) National Collaborating Centre for Cancer.
<https://www.nice.org.uk/guidance/ng12>
- Orloff, L. A., Wiseman, S. M., Bernet, V. J., Fahey, T. J., 3rd, Shaha, A. R., Shindo, M. L.,
 Snyder, S. K., Stack, B. C., Jr., Sunwoo, J. B., & Wang, M. B. (2018). American
 Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis,
 Prevention, and Management in Adults. *Thyroid*, 28(7), 830-841.
<https://doi.org/10.1089/thy.2017.0309>
- Pak, C. Y. C., Kaplan, R., Bone, H., Townsend, J., & Waters, O. (1975). A Simple Test for
 the Diagnosis of Absorptive, Resorptive and Renal Hypercalciurias. *New England
 Journal of Medicine*, 292(10), 497-500.
<https://doi.org/10.1056/NEJM197503062921002>
- Pearle, M. S., Goldfarb, D. S., Assimos, D. G., Curhan, G., Denu-Ciocca, C. J., Matlaga,
 B. R., Monga, M., Penniston, K. L., Preminger, G. M., Turk, T. M. T., & White, J. R.
 (2019). Medical Management of Kidney Stones: AUA Guideline. *Journal of Urology*.
[https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-
 medical-mangement-guideline](https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-medical-mangement-guideline)
- Press, D. M., Siperstein, A. E., Berber, E., Shin, J. J., Metzger, R., Monteiro, R., Mino, J.,
 Swagel, W., & Mitchell, J. C. (2013). The prevalence of undiagnosed and

- unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. *Surgery*, 154(6), 1232-1237; discussion 1237-1238. <https://doi.org/10.1016/j.surg.2013.06.051>
- Quamme, G. A. (1986). Renal handling of magnesium: drug and hormone interactions. *Magnesium*, 5(5-6), 248-272. <https://www.ncbi.nlm.nih.gov/pubmed/3543513>
- Rodriguez-Ortiz, M. E., Canalejo, A., Herencia, C., Martinez-Moreno, J. M., Peralta-Ramirez, A., Perez-Martinez, P., Navarro-Gonzalez, J. F., Rodriguez, M., Peter, M., Gundlach, K., Steppan, S., Passlick-Deetjen, J., Munoz-Castaneda, J. R., & Almaden, Y. (2014). Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. *Nephrol Dial Transplant*, 29(2), 282-289. <https://doi.org/10.1093/ndt/gft400>
- Rooney, M. R., Alonso, A., Folsom, A. R., Michos, E. D., Rebholz, C. M., Misialek, J. R., Chen, L. Y., Dudley, S., & Lutsey, P. L. (2020). Serum magnesium and the incidence of coronary artery disease over a median 27 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study and a meta-analysis. *Am J Clin Nutr*, 111(1), 52-60. <https://doi.org/10.1093/ajcn/nqz256>
- Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., & Walter, M. A. (2016). 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid*, 26(10), 1343-1421. <https://doi.org/10.1089/thy.2016.0229>
- Shaker, J. L., & Deftos, L. (2023). Calcium and Phosphate Homeostasis. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J. E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D. L. Trencce, A. Vinik, & D. P. Wilson (Eds.), *Endotext*. MDText.com, Inc. <https://www.ncbi.nlm.nih.gov/books/NBK279023/>
- Singh., A. G. C. A. M. N. S. (2023). Hypocalcemia. <https://www.ncbi.nlm.nih.gov/books/NBK430912/>
- Sri-Ganeshan, M., Walker, K. P., Lines, T. J., Neal-Williams, T. J. L., Sheffield, E. R., Yeoh, M. J., & Taylor, D. M. (2022). Evaluation of a calcium, magnesium and phosphate clinical ordering tool in the emergency department. *Am J Emerg Med*, 53, 163-167. <https://doi.org/10.1016/j.ajem.2022.01.003>
- Sturgeon, C. M., Sprague, S., Almond, A., Cavalier, E., Fraser, W. D., Algeciras-Schimnich, A., Singh, R., Souberbielle, J. C., & Vesper, H. W. (2017). Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. *Clin Chim Acta*, 467, 42-47. <https://doi.org/10.1016/j.cca.2016.10.016>
- Tieder, J. S., Bonkowsky, J. L., Etzel, R. A., Franklin, W. H., Gremse, D. A., Herman, B., Katz, E. S., Krilov, L. R., Merritt, J. L., 2nd, Norlin, C., Percelay, J., Sapien, R. E., Shiffman, R. N., & Smith, M. B. (2016). Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants. *Pediatrics*, 137(5). <https://doi.org/10.1542/peds.2016-0590>
- Valcour, A., Zierold, C., Blocki, F. A., Hawkins, D. M., Martin, K. J., Rao, S. D., & Bonelli, F. (2018). Trueness, precision and stability of the LIAISON 1-84 parathyroid

hormone (PTH) third-generation assay: comparison to existing intact PTH assays. *Clin Chem Lab Med*. <https://doi.org/10.1515/cclm-2018-0217>

Wilhelm, S. M., Wang, T. S., Ruan, D. T., Lee, J. A., Asa, S. L., Duh, Q.-Y., Doherty, G. M., Herrera, M. F., Pasiaka, J. L., Perrier, N. D., Silverberg, S. J., Solórzano, C. C., Sturgeon, C., Tublin, M. E., Udelsman, R., & Carty, S. E. (2016). The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. *JAMA Surgery*, *151*(10), 959-968. <https://doi.org/10.1001/jamasurg.2016.2310>

Wojda, S. J., & Donahue, S. W. (2018). Parathyroid hormone for bone regeneration. *J Orthop Res*, *36*(10), 2586-2594. <https://doi.org/10.1002/jor.24075>

Workinger, J. L., Doyle, R. P., & Bortz, J. (2018). Challenges in the Diagnosis of Magnesium Status. *Nutrients*, *10*(9), 1202. <https://doi.org/10.3390/nu10091202>

Wright, M., Southcott, E., MacLaughlin, H., & Wineberg, S. (2019). Clinical practice guideline on undernutrition in chronic kidney disease. *BMC Nephrol*, *20*(1), 370. <https://doi.org/10.1186/s12882-019-1530-8>

Policy Update History:

Approval Date	Effective Date: Summary of Revisions
04/29/2024	01/15/2025: Document updated with literature review. Reimbursement information unchanged. References revised.
06/15/2023	06/15/2023: Document updated with literature review. Reimbursement information revised for clarity. References revised; some added, others removed.
11/1/2022	11/01/2022: New policy